French (CAC) Biotech Industry Analysis

Industry Valuation and Performance

Has the French Biotech Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Tue, 23 Jun 2026	€9.4b	€507.6m	-€879,795,600.79	16.8x	-10.7x	18.5x
Thu, 21 May 2026	€11.2b	€494.2m	-€857,777,007.09	16.4x	-13x	22.6x
Sat, 18 Apr 2026	€11.2b	€502.0m	-€816,293,336.02	16.7x	-13.7x	22.3x
Mon, 16 Mar 2026	€11.3b	€562.3m	-€767,160,386.14	12.7x	-14.7x	20.1x
Wed, 11 Feb 2026	€11.3b	€558.9m	-€762,066,158.30	13.7x	-14.9x	20.3x
Fri, 09 Jan 2026	€10.5b	€642.1m	-€695,020,428.50	9.4x	-15.1x	16.4x
Sun, 07 Dec 2025	€2.5b	€637.0m	-€431,023,295.27	10.5x	-5.9x	4x
Tue, 04 Nov 2025	€2.5b	€637.5m	-€423,324,083.10	10.2x	-5.8x	3.8x
Thu, 02 Oct 2025	€2.5b	€643.2m	-€443,605,881.65	15.7x	-5.7x	3.9x
Sat, 30 Aug 2025	€2.4b	€673.8m	-€445,298,569.79	14.9x	-5.4x	3.6x
Mon, 28 Jul 2025	€2.2b	€655.5m	-€451,422,772.75	15.2x	-4.8x	3.3x
Wed, 25 Jun 2025	€1.9b	€666.3m	-€495,127,696.44	17.2x	-3.8x	2.8x
Fri, 23 May 2025	€2.4b	€673.7m	-€676,392,752.17	16.4x	-3.5x	3.5x
Sun, 20 Apr 2025	€2.2b	€650.7m	-€551,057,719.37	13.8x	-4.1x	3.4x
Tue, 18 Mar 2025	€2.3b	€664.1m	-€478,532,955.72	16.5x	-4.8x	3.5x
Thu, 13 Feb 2025	€2.6b	€650.2m	-€527,020,285.66	17x	-4.9x	4x
Sat, 11 Jan 2025	€2.4b	€650.7m	-€529,300,364.55	18.2x	-4.5x	3.6x
Mon, 09 Dec 2024	€2.4b	€654.2m	-€547,506,002.19	17.8x	-4.4x	3.7x
Wed, 06 Nov 2024	€2.8b	€655.2m	-€550,952,005.39	18.1x	-5x	4.2x
Fri, 04 Oct 2024	€2.7b	€627.0m	-€509,701,001.49	19x	-5.4x	4.3x
Sun, 01 Sep 2024	€3.2b	€520.6m	-€580,616,061.13	37.1x	-5.5x	6.1x
Tue, 30 Jul 2024	€2.9b	€511.8m	-€567,167,702.24	29x	-5.1x	5.7x
Thu, 27 Jun 2024	€2.9b	€514.4m	-€569,793,303.89	26.2x	-5.1x	5.7x
Sat, 25 May 2024	€3.4b	€502.4m	-€592,943,807.34	28.4x	-5.8x	6.8x
Mon, 22 Apr 2024	€3.2b	€515.6m	-€629,088,205.81	27.2x	-5.1x	6.2x
Wed, 20 Mar 2024	€3.2b	€567.9m	-€646,218,011.98	21.8x	-4.9x	5.5x
Fri, 16 Feb 2024	€3.1b	€558.9m	-€674,978,897.03	22.6x	-4.6x	5.6x
Sun, 14 Jan 2024	€3.1b	€594.2m	-€683,192,676.00	23.6x	-4.5x	5.2x
Tue, 12 Dec 2023	€3.2b	€594.8m	-€686,269,454.00	21.8x	-4.6x	5.4x
Thu, 09 Nov 2023	€3.4b	€803.2m	-€579,110,359.00	21.9x	-5.8x	4.2x
Sat, 07 Oct 2023	€3.2b	€831.2m	-€598,674,575.00	14.1x	-5.3x	3.8x
Mon, 04 Sep 2023	€3.9b	€818.3m	-€727,820,392.00	25.2x	-5.3x	4.7x
Wed, 02 Aug 2023	€3.7b	€818.4m	-€737,097,203.00	24.8x	-5.1x	4.6x
Fri, 30 Jun 2023	€3.7b	€819.9m	-€744,336,187.00	25.3x	-5x	4.6x

Current Industry PE

Investors are optimistic on the French Biotechs industry, and appear confident in long term growth rates.

The 3-year average PS ratio of 7.2x is lower than the industry's current PS ratio of 18.5x.

Past Earnings Growth

The earnings for companies in the Biotechs industry have deteriorated over the last three years.
Revenues have also declined 15% per year.
This means overall sales from these companies are declining and losses are subsequently expanding as well.

Industry Trends

Which industries have driven the changes within the French Healthcare industry?


FR Market	-0.75%
Healthcare	-4.97%
Biotech	-1.47%
Biotech	-1.47%

Industry PEThere are no additional sub-industries under this industry.

Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
ABVX ABIVAX Société Anonyme	€85.80	0.8% +€55.8m	1,556.4%	PS1389.8x
GNFT Genfit	€10.72	10.6% +€51.3m	219.8%	PS8.2x
IPH Innate Pharma	€1.61	4.1% +€6.0m	5.5%	PS16.8x
ALVIO Valerio Therapeutics Société anonyme	€0.20	4.7% +€4.5m	203.0%	PS38.8x
VLA Valneva	€2.31	0.6% +€2.5m	-2.3%	PS2.8x

Genfit Launches Nashnext Test Powered by Nis4 Technology Via Labcorp Ondemand for Identification of At-Risk Mash

GENFIT announced that access to Labcorp’s NASHnext, a diagnostic test to identify at-risk MASH (Metabolic dysfunction-Associated SteatoHepatitis), powered by GENFIT’s proprietary non-invasive diagnostic technology NIS4, is now available through Labcorp OnDemand. Labcorp’s platform allows patients expanded access to certain diagnostic tests online, which a physician can approve and review without requiring an in-person doctor's visit. GENFIT’s non-invasive technology was specifically designed to identify patients with at-risk MASH and is able to power a test that can capture both disease activity and fibrotic burden even if still at F2 (stage 2 fibrosis), thus providing helpful information to support clinical evaluation, diagnosis, and treatment decisions. By enabling earlier and more accurate identification of at-risk patients, this approach helps address key diagnostic gaps across primary care, endocrinology, and broader clinical settings. Labcorp’s NASHnext is now available through Labcorp OnDemand, a digital interface for patients that provides them with an additional access channel to healthcare professionals within the routine care framework, with all testing requests reviewed by a healthcare professional. It is intended to broaden access to testing in the United States, in anticipation of a reimbursement decision by Medicare/Medicaid that would enable access across relevant patient populations. NASHnext testing could be useful to a U.S. patient population in the high tens of millions of individuals, reflecting the need to screen broadly to identify patients with at-risk MASH. This estimate is informed by the high and growing prevalence of metabolic risk factors in the U.S., including type 2 diabetes, obesity, or dyslipidemia, with a clear majority of adults presenting at least one such risk factor. Within this large population, a significant proportion already presents with elevated liver markers, and a subset may ultimately be eligible for treatment, with potential additional use in monitoring. NASHnext evaluates multiple blood-based markers associated with liver fat, inflammation, and liver fibrosis. Unlike routine liver enzyme tests alone, this approach looks at how several markers relate to each other. Results are intended to support clinical follow-up and monitoring decisions when interpreted by a healthcare provider and are only one part of a broader liver health evaluation. In practice, via the OnDemand platform, patients can order the test online, go to a patient service center for the blood draw, and see their test results rapidly on MyLabcorp app. With a high and growing prevalence of metabolic risk factors in the U.S., early detection of at-risk MASH could benefit a U.S. patient population in the high tens of millions of individuals, highlighting a significant unmet medical need. Liver biopsy currently remains the clinical standard for diagnosing at-risk MASH, but its use is highly constrained by its invasive and costly nature and difficult scalability. Labcorp’s NASHnext is a non-invasive diagnostic test to easily identify patients with at-risk MASH (Metabolic dysfunction-Associated SteatoHepatitis). It is powered by GENFIT’s proprietary non-invasive diagnostic technology NIS4. NIS4 and next-generation technology NIS2+ have been widely recognized over the past few years as showing a unique performance in identifying patients with at-risk MASH. This recognition is reflected through a growing body of scientific evidence (including publications in The Lancet and Nature Medicine), inclusion in joint guidelines from several international scientific societies (EASL-EASD-EASO), strong visibility within major consortia in the U.S. and Europe (NIMBLE and LITMUS), and its use in most large clinical trials conducted by key industry players in MASH. GENFIT is actively seeking to advance partnerships with pharmaceutical companies to support wider deployment of non-invasive testing for at-risk MASH and accelerate adoption in line with the expansion of MASH therapies. GENFIT is also exploring the development of an IVD-labeled (In Vitro Diagnostic) version of its non-invasive diagnostic technology, either independently or in collaboration with a diagnostic-focused partner, with the selected approach expected to reflect the most appropriate route to maximize long-term value for GENFIT.

French (CAC) Biotech Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

New minor risk - Market cap size

Abivax Stock Rises on Positive Phase 3 Obefazimod Results and Strong Cash Position Through 2027

Nicox Announces Positive Pre-Submission Regulatory Feedback in China Supporting NDA Filing for NCX 470

Valerio Therapeutics Société Anonyme Announces Board and Executive Changes

IVA: Equity Raise And New Financing Will Support Upcoming MASH Milestones

DBV Technologies Starts Infant Peanut Allergy Trial and Reports Positive Phase 3 Results

VLA: Future Travel Vaccines And Lyme Franchise Will Drive Reassessment

Consensus revenue estimates fall by 28%

Cellectis S.A. Presents Final Phase 1 Results of Lasme-Cel and Preliminary Results on Eti-Cel At Eha 2026 Congress

Adocia Presents Full Phase 3 Results For BioChaperone Lispro In Type 2 Diabetes Presented at ADA 86th Scientific Sessions

Genfit Launches Nashnext Test Powered by Nis4 Technology Via Labcorp Ondemand for Identification of At-Risk Mash

IPH: 2026 Oncology Readouts Will Drive Reassessment Of Risk Reward Profile

Nanobiotix Raises US$100 Million in Oversubscribed Global Offering to Fund Oncology Programs

Eurobio Scientific Société anonyme, Annual General Meeting, Jun 18, 2026

GenSight Biologics S.A., Annual General Meeting, May 19, 2026